In vitro anticancer activity of hydrogen sulfide and nitric oxide alongside nickel nanoparticle and novel mutations in their genes in CRC patients

Zjwan Housein1,2, Tayeb Sabir Kareem3 & Abbas Salihi1,4*

This study was carried out to assess the impact of nickel nanoparticles (NiNPs) as well as scorpion venom on colorectal cancer (CRC) cells in the presence and/or absence of 5-fluorouracil (5-FU), hydrogen sulfide (H2S), and nitric oxide (NO) donors and to determine alterations in endothelial NO synthase (eNOS) and cystathionine γ-lyase (CSE) enzyme-producing genes in CRC patients. The IC50 of both H2S and NO donors, along with NiNPs, were determined. The CRC cells were treated for 24hrs, and the cytotoxic activities were assessed using the MTT test. Moreover, the apoptosis was determined after 24hrs and 48hrs using TUNEL assay. Furthermore, the mutations in the eNOS gene (intron 4, -786T>C and 894 G>T) and CSE gene (1364GT) were determined using direct sequencing. The IC50 values for sodium disulfide (Na2S) and sodium nitroprusside (SNP) at 24hrs treatment were found to be 5 mM and 10−6 M, respectively, while the IC50 value for 5-FU was reached after 5-days of treatment in CRC cell line. Both black and yellow scorpion venoms showed no inhibition of cell proliferation after 24hrs treatment. Furthermore, Na2S showed a significant decrease in cell proliferation and an increase in apoptosis. Moreover, a co-treatment of SNP and 5-FU resulted in inhibition of the cytotoxic effect of 5-FU, while a combination treatment of NiNPs with Na2S, SNP, and 5-FU caused highly significant cytotoxicity. Direct sequencing reveals new mutations, mainly intronic variation in eNOS gene that has not previously been described in the database. These findings indicate that H2S promotes the anticancer efficiency of 5-FU in the presence of NiNPs while NO has antiapoptotic activity in CRC cell lines.

In the world, colorectal cancer, generally known as colorectal adenocarcinoma, is the third foremost identified malignant tumour and the second most common cause of cancer death with variation within world regions1,2. Contemporary, there is insufficient data available about the prevalence and deaths of CRC in the entire Kurdistan region of Iraq1. The first report about CRC incidence in Kurdistan found an increase in annual incidence throughout 2007–20094. According to a study accomplished in the Kurdistan region of Iraq, CRC is the top four most common cancer type for both genders, and the mortality rate was 8.6% compared to the worldwide estimated mortality which is 9.2%1,5.

Hitherto, the stage of CRC is the most vital prognostic factor for surviving this disease and the treatment procedures for CRC are mainly surgical resection as long as cancer has not spread to distant organs followed by chemotherapy if necessary6,7. Over the last three decades, 5-FU is used as a core chemotherapy drug to treat patients suffering from CRC8. Other treatments like radiotherapy9, ancillary anticancer medicines to prevent relapse10, and combination treatments11 are applied to treat patients in a more advanced stage of CRC. Nevertheless, all these therapy pathways have their drawbacks; therefore, innovative therapeutic approaches are requested urgently12. Hence, investigators focused on natural resources such as scorpion venoms that contain a blend of toxins and catalytic enzymes which exhibit anticancer activities, and therefore, are considered a potential...
candidate for developing new drugs that could enhance the effectiveness of conventional therapy and enable reduction of high doses of chemotherapy drugs intake. Recent researches are focused on tumour targeting through nanotechnology, which is a novel strategy and is a promising tool for the treatment of CRC. Nanoparticles are small in size and therefore transport easily through the cell and could remain inside the cancerous cell and destroy it with limited damage to the healthy cells and tissues. This target-specific character is an important factor for developing nanodrug for the treatment of colorectal cancer; however, there are limited studies available that evaluate the cytotoxicity of nickel nanoparticles (NiNPs) on CRC cells.

Hydrogen sulfide (H₂S) and Nitric oxide (NO) are gaseous molecules known as “gasotransmitters” in human biology and regulation of cancer-related events such as proliferation, angiogenesis, cell apoptosis, and metastasis. Different enzymes endogenously catalyze each of these molecules in various cell types. H₂S is mainly raised from the amino acids L-cysteine by two separate enzymes cystathionine γ-lyase (CSE) and cystathionine β-synthase (CBS). At the same time, NO is enzymatically catalyzed by one of the four major isoforms of NO synthases, namely neuronal NOS, inducible NOS (iNOS), and endothelial NOS (εNOS) and lately mitochondrial NOS from the amino acid L-arginine and oxygen. H₂S and NO reveal the exceptional capability to diffuse free through the cell membranes, accordingly acting as regulatory signalling molecules and it turns out to have a paradoxical effect in the cells, being either promotive or suppressive reliant on cell types and the concentration and which pathway is consequently activated.

The findings in studies regarding the effect of NO and H₂S on CRC cell death and related angiogenesis are ambiguous. Hence, this study aims to find out the impact of venoms and nickel nanoparticles (NiNPs) on CRC cells treated with or without 5-FU, H₂S, and NO donors or a combination of these treatments. Furthermore, to evaluate the genotypic variations and polymorphisms in eNOS and CSE enzyme-producing genes in CRC patients.

**Results**

**Anticancer activity of scorpion’s venom.** The in vitro cytotoxic effect of crude black scorpion venom (*Androctonus Crassicauda*) and yellow scorpion venom (*Hottentotta Saulcyi*) was conducted in a dose-dependent manner using CRC cell line (HT-29). The indirect measure of cell viability was determined using MTT assay. Both scorpion venoms showed no inhibition of cell proliferation after 24hrs treatment (Fig. 1).

**Anticancer activity 5-FU, Na₂S, and SNP.** The cytotoxic effect of 5-FU, Na₂S, and SNP was determined in a dose-dependent manner to obtain an appropriate concentration of these agents for 50% cell death using MTT assay. This dose concentration represents the IC₅₀ of that specific agent in the HT-29 CRC cell line after 24hrs of exposure. The cell viability of each drug or agent and after treatment with the particular drug or agent or a combination of treatment were assessed. The IC₅₀ values for Na₂S and SNP at 24hrs treatment were found to be 5 mM and 10⁻⁶ M, respectively. Furthermore, we confirmed that the IC₅₀ value for 5-FU was 11.25 µM and reached after 5-days of treatment in the case of the HT-29 cell line.

Next, we investigated the cytotoxic effect of these agents and the drug individually or in combination treatments on the HT-29 CRC cell line (Fig. 2). Our result presents the highly significant (P < 0.001) cytotoxic effect of 5-FU and a combination of 5-FU and Na₂S compared to the control cells. At the same time, treatment with 5-FU and a combination of Na₂S and SNP shows significant (P < 0.05) more cell death compared to cells treated with individual Na₂S. Moreover, a co-treatment of Na₂S and 5-FU shows a highly significant (P < 0.001) cytotoxic effect compared to cells treated with only Na₂S.

A further data analysis showed that co-treatment of Na₂S and SNP causes highly significant (P < 0.001) cytotoxicity compared to cells treated with only 5-FU, whereas co-treatment of 5-FU and SNP decreases (P < 0.01) the cytotoxic effect compared to 5-FU, but the effect remains significant.
Our data also shows that co-treatment of Na$_2$S and SNP induces a highly significant ($P<0.001$) cytotoxic effect compared to a co-treatment of 5-FU and Na$_2$S. While there is a decrease in cell cytotoxicity in co-treatment of 5-FU, Na$_2$S, and SNP ($P<0.05$) compared to Na$_2$S and SNP treated group. Finally, CRC cells treated with a combination of 5-FU and Na$_2$S show a highly significant ($P<0.001$) cytotoxic effect compared with the co-treatment of 5-FU and SNP.

**Anticancer activity NiNPs.** We also investigated the cytotoxic effect of NiNPs on the HT-29 cell line using MTT assay for 24hrs (Fig. 3). Individual NiNP treatment has no cytotoxic activity in the HT-29 CRC cell line. In contrast, there is a highly significant increase ($P<0.001$) in cytotoxicity in cells treated with a combination of H$_2$S, SNP, 5-FU, and NiNP compared to the control group. The further data analysis showed that there is a significant increase ($P<0.01$, $P<0.05$, and $P<0.05$) in cytotoxicity of cells co-treated with Na$_2$S, SNP, 5-FU, and NiNP compared to co-treatments Na$_2$S, NiNP; SNP, NiNP, and SNP; Na$_2$S and NiNP, respectively.

**Antiapoptotic activity 5-FU, Na$_2$S, and SNP.** The DNA fragmentation results after 24 h incubation (Fig. 4) showed DNA fragmentation around 1–2%, in the control group, while the tunnel staining presented an increase of DNA fragmentation to 12% after treatment with Na$_2$S. Besides, tunnel staining exhibited an antiapoptotic effect of CRC cells treated with SNP. Treating the cells with 5-FU causes total destroying of CRC cells after 24hrs, therefore only the debris of cells was visible in the slides. This result was almost the same for cells treated with both 5-FU and Na$_2$S. In the presence of SNP agent, the cytotoxic effect of 5-FU is inhibited, and more CRC cells survived. The effect of a triple combination of 5-FU, Na$_2$S, and SNP showed a distinctly decrease in cell survival, and more DNA fragmentation was visible.

We then investigated the DNA fragmentation after incubation of cells for 48hrs with Na$_2$S, a slightly increased DNA fragmentation was shown compared to 24hrs exposure (Fig. 5).
Genetic polymorphisms of eNOS and CBS. The result of gel electrophoresis in which the PCR product was separated in a 3% gel concentration, showed differences in the thickness of the amplicon. However, we were not able to distinguish between the heterozygous and homozygous variants. Therefore, we decided to genotype the three different single nucleotide polymorphisms in the eNOS gene and one in the CSE gene. Following DNA sequencing, we analyzed the mutations in eNOS and CSE gene using Mutation Surveyor (Table 1).

In total, we validated 19 mutations in the 27-bp repeat polymorphism in intron 4 (27 bp-VNTR) of the eNOS gene at a different position on chromosome 7. The most nucleotide substitution that occurred in the 27 bp-VNTR was five times A→G. The variant mutation (c.582+317A>G) on chromosome position 7:150694330 has been previously described in external public databases such as dbSNP, gnomAD (Table 1). However, the A→G substitution in the mutation variants (c.582+360A>G, c.582+363C>A and c.582+362A>G) were not found in the external databases.

The T→G substitution (c.582+357T>G) on chromosome position 7:150694370 has occurred in two different CRC patients, and this mutation has been previously described; while, the T→G substitution with mutation variant (c.582+376T>G) that occurred on chromosome position 7:150694389, in which this mutation was not found previously in the databases mentioned above. However, the intronic nucleotide substitution A→C (582+355A>C)
and G→A (c.582+356G>A) took place in the equal frequency of two, and G→C substitution (c.582+375G>C) turned out to occur only once in our patients that has not earlier been described in the databases. Correspondingly, two deletions occurred in intron 4 including a single nucleotide deletion A (c.582+360delA) along with ten nucleotide deletions (c.582+374del TGC TGC GGGG). Furthermore, an heterozygous insertion of twenty-eight nucleotides occurred in intron 4 (c.582+381_c.582+382het_ins AGT CTA AAC CTA CTG CGG GGG TGA GGA) followed by a duplication of nucleotide A (c.582+620dupA). All these deletions and insertions found in intron 4, were not described previously in external databases. The G→A substitution that leads to homozygous mutation genotype were found in intron 4, and this mutation has been described in both dbSNP and gnomAD database. Alongside the Intronic mutations in the eNOS locus, we studied mutations in a T to C single nucleotide polymorphism (SNP) in the promoter region (T-786C, rs2070744). We found six times the heterozygous nucleotide substitution C>T (c.-51-762C>T) and two homozygous mutations that have been previously described in a public database (Table 1). The difference between the homozygous and heterozygous substitution is demonstrated in Fig. 6a,b, respectively. Besides, we determined the genotype of G→T (Glu298Asp; rs1799983) polymorphisms in exon 7 of eNOS. Further analysis of our data revealed that a missense mutation occurred in 2 out of 5 patients in which guanine is replaced by thymine at exon 7 that leads to a different codon that changes the amino acid Glutamate into Aspartate at codon position 298. This mutation is known in the external database, and this missense mutation is shown in Fig. 6c

Last but not least, we identified a common single nucleotide polymorphism, namely c.1364G>T in exon 12 of CSE, rs1021737 in CRC patients. The missense heterozygous SNPs (c.1208G>GT) on chromosome position1:70904800 causing a change in amino acid Ser to Ile at position codon position 1218 (Fig. 6d) and this mutation is earlier described in databases such as gnomAD, ClinVar, and dbSNP, while mutation variant (c.1218+247G>GA) that occurred on chromosome position 1:70905057 have not been found in database.

### Table 1. Variants identified in CRC patients analyzed with mutation DNA variant analysis.

| Gene   | Chromosome position | Mutation | Mutation genotype | Heterozygous/ homozygous | Variants | Amino Acid change | Molecular consequence | External database |
|--------|---------------------|----------|-------------------|--------------------------|----------|------------------|----------------------|-------------------|
| eNOS   | 7:150,694,330       | A>AG     | AG                | Heterozygous            | c.582+317A>G | N/A               | Intron variant       | gnomAD,dbSNP |
|        | 7:150,694,368       | A>AC     | AC                | Heterozygous            | c.582+355A>C | N/A               | Intron variant       | Not found |
|        | 7:150,694,369       | G>GA     | GA                | Heterozygous            | c.582+356G>A | N/A               | Intron variant       | Not found |
|        | 7:150,694,370       | T>G      | TG                | Heterozygous            | c.582+357T>G | N/A               | Intron variant       | dbSNP |
|        | 7:150,694,373       | Deletion A| -A                |                           | c.582+360delA | N/A               | Intron variant       | Not found |
|        | 7:150,694,373       | A>AG     | AG                | Heterozygous            | c.582+360A>G | N/A               | Intron variant       | Not found |
|        | 7:150,694,376       | C>AG     | AG                | Heterozygous            | c.582+363C>A+582+363C>G | N/A               | Intron variant       | Not found |
|        | 7:150,694,374       | G>A      | AA                | Heterozygous            | c.582+361G>+582+361G>A | N/A               | Intron variant       | gnomAD,dbSNP |
|        | 7:150694378_7:150694387 | del TGTGCGGGGG | - | - | c.582+356 c.582+374 del TGTGCGGGGG | N/A | Intron variant | Not found |
|        | 7:150,694,385       | A>AG     | AG                | Heterozygous            | c.582+362A>G | N/A               | Intron variant       | Not found |
|        | 7:150,694,378       | G>GC     | GC                | Heterozygous            | c.582+375G>C | N/A               | Intron variant       | Not found |
|        | 7:150694394_7:150694395 | insertion AGT CTA AAC CTA CTG CGG GGG TGA GGA | + | Heterozygous | c.582+381 c.582+382het_ins AGTCTAAACCTACTGGCGGGGGTGGAGGA | N/A | Intron variant | Not found |
|        | 7:150,694,387       | T>G      | TG                | Heterozygous            | c.582+376T>G | N/A               | Intron variant       | genomAD,dbSNP |
|        | 7:150,694,633       | Duplication A | ++ | Heterozygous | c.582+620dupA | N/A | Intron variant | Not found |
| VNTR4  | 7:150694394_7:150694395 | insertion AGT CTA AAC CTA CTG CGG GGG TGA GGA | + | Heterozygous | c.582+381 c.582+382het_ins AGTCTAAACCTACTGGCGGGGGTGGAGGA | N/A | Intron variant | Not found |
|        | 7:150,694,388       | T>G      | TG                | Heterozygous            | c.582+376T>G | N/A               | Intron variant       | dbSNP |
| eNOS   | rs2070744 (T-786C)  | C>CT     | CT                | Heterozygous            | c.51-762C>T | N/A               | Generic Upstream Transcription Variant | dbSNP |
|        | 7:150,690,079       | C>T      | TT                | Heterozygous            | c.51-762C>T | N/A               | dbSNP |
| eNOS   | rs1799983 (G894T)   | T>G      | TG                | Heterozygous            | c.894T>G   | (Glu298Asp) Missense variant | dbSNP |
| CTH    | Rs1021737 (1364G-T) | G>GA     | GA                | Heterozygous            | c.1218+247G>A | (Ser403Ile) Missense variant Missense variant Not found | dbSNP |
|        | 1:70,904,800        | G>GT     | GT                | Heterozygous            | c.1208G>T  | (Ser403Ile) Missense variant | dbSNP |
|        | 1:70,905,057        | G>GA     | GA                | Heterozygous            | c.1218+247G>A | (Ser403Ile) Missense variant | dbSNP |

Scientific Reports | (2022) 11:2536 | https://doi.org/10.1038/s41598-021-82244-x | natureportfolio
Discussion

Colorectal cancer remains one of the most common cancers in humans with high incidence and mortality across the world. The existing conventional chemotherapeutic agents exhibit shortcomings due to the lack of selective targeting of cancerous cells. For this reason, researchers are working towards target therapy for the development of the most effective treatment.

For decades, scorpion venom has been used in traditional treatments, and recently researchers exhibited the anticancer properties of scorpion venom. In this study, we examined the cytotoxic effect of the crude scorpion venoms, including *Androctonus Crassicauda* and *Hottentotta Saulcyi* on the CRC cell line (HT-29). The findings of this study showed no inhibition of cell proliferation after 24hrs treatment with high concentrations of scorpion venoms. This result is in contrast to previous studies wherein they showed cytotoxicity and cell cycle arrest of scorpion venom (*Androctonus bicolor*) on breast and CRC cell lines. Moreover, Zargan et al. used

![Figure 6. Graphical display of identified SNPs in eNOS and CSE gene (Sanger sequencing and analysis by mutation Surveyor software version 5.1. intronic mutation (VNTR4). Line 1 represents the forward reference trace Line 2 the patient DNA trace and line 3 the mutation trace and the arrow show the nucleotide substitution. (A) shows the heterozygous mutation -786T>C (c.-51-762C>T). (B) homozygous (T-786C) (c.-51-762C>T). (C) homozygous mutation in SNP G896T that leads to amino acid change (Glu298ASP) and (D) shows the mutation in SNP (364G-T) of the CSE gene that leads to amino acid change (Ser403Ile).](image-url)
**Androctonus crassicauda** scorpion, and their findings showed cytotoxicity and cell cycle arrest in the transformed breast cancer cell line.  

Moreover, a variety of anticancer effects such as inducing apoptosis, cell cycle arrest, along with inhibition of invasion, metastasis, and angiogenesis in cancer cells, which are all targets of hallmarks of cancer alters when a variety of cell lines are treated with different bioactive peptides of scorpion venom, as reviewed recently. The disability of both venom in this study to cause cytotoxicity could attribute to the venom preparation in this explicit investigational setup, where the venom is directly used after extraction from the scorpion without freeze-drying.

One of the main chemotherapeutic treatments for CRC includes 5-FU. The current result shows highly significant cytotoxicity of 5-FU on the HT-29 cell line. This is in consonance with the recently published work by Attoub et al. wherein they demonstrate a reduction of different human CRC cells after treatment with 5-FU. Nonetheless, the clinical application of 5-FU often causes chemoresistance. Therefore, it is necessary to pursue combination therapy to minimize the side effects that occur in patients. The precise role of gasotransmitters H2S and NO in cancer remains debatable and demands further attention. Several studies have ascertained that NO and H2S have a dichotomous role in cancer, either promoting growth and proliferation. In contrast, others suggest antitumor effects such as inhibition of cell proliferation and suppression of DNA synthesis of the cancer cells as remarked by Kashefi in a recent review. Given the positive role of these two gasotransmitters in the inhibition of cancer cell proliferation, in the present study, we have investigated the effect of NO and H2S donors individually or in combination with 5-FU on the HT-29 cell line for 24hrs. Our data illustrates that Na2S significantly increases the cytotoxicity of HT-29 cells after combination with 5-FU compared to untreated cells. The findings in this study are in a similar vein with Olaah et al., who claim that using an increased level of H2S above the optimum concentration suppresses CRC cell proliferation. However, this result is not in line with Szabo et al., who depict that H2S stimulates tumour progression in the CRC cell line. In the same way as H2S, we examined the cytotoxic effect of NO donor SNP on the CRC cell line. The result shows no cytotoxicity of SNP on HT-29 cells compared to untreated cells while eradicates the cytotoxic effect of 5-FU. The latter findings might indicate that SNP acts as an antiapoptotic agent and probably interact with 5-FU and abolish the cytotoxic effect of 5-FU, which makes HT-29 cells resistant to 5-FU. According to a recent review, NO acts according to the bell-shape model in a concentration-dependent manner similar to H2S. The interaction between H2S and NO that leads to the production of H2Sn has recently been studied and has shown that it could affect several physiological events such as activation of a particular tumour suppressor gene. Therefore, it is important to study the effects of H2Sn in CRC cell lines and find the mechanism of action in future studies. Furthermore, the findings of a study that used a hybrid molecule containing nitric oxide and H2S combined with aspirin (NOSH-aspirin) which has anti-tumour properties demonstrated a synergistic effect with 5-FU treatment in xenograft model of colon cancer.

To study the apoptosis induction from a different endpoint, we measured DNA fragmentation using the TUNEL assay. The results demonstrated a ten-fold increase in DNA fragmentation in HT-29 cells treated with Na2S compared to the untreated cells, while 100% of the cells were killed using 5-FU or co-treatment with Na2S and 5-FU. Our finding is in agreement with recently published in vivo work, wherein they demonstrate a significant increase in TUNEL positive cells after inhibition of CBS. Earlier published work has shown CBS to be overexpressed and promote cell proliferation and stimulate angiogenesis in CRC patients. These findings might propose the fact that these agents are acting as prosapoptotic agents and could be a suitable candidate for future target therapy against CRC. In the meantime, treating HT-29 cells with SNP for 24hrs and 48hrs did not demonstrate any DNA breakage, while a co-treatment with 5-FU and SNP more cells survived. The latter finding is in line with our anticancer activity result wherein no effect of SNP was determined, and SNP neglected the cytotoxic effect of 5-FU. Besides, a triple combination treatment of 5-FU, SNP, and Na2S showed an increase in DNA fragmentation and a decrease in cell survival. Perhaps, H2S could be considered as a potent anticancer agent.

Nanoparticles have gained immense attention in the field of cancer therapy due to their small size and highly reactive and specific feature, and due to its target-specific character, it enables a personalized treatment as described in two separate reviews. Having discussed the positive role of NO and H2S in colon cancer, we aimed to observe the anticancer activity of NiNP on HT-29 cells by measuring the cytotoxicity of the particles and in combination with 5-FU and the donors of these two gasotransmitters. Our result showed that there is no significant difference in cell survival after exposure of CRC cells to NiNP for 24hrs, while co-treatment of NiNP with 5-FU, Na2S, and SNP shows a significant increase in cytotoxicity. Of note, SNP does not inhibit 5-FU cytotoxicity. These findings are inconsistent with a recently published work where they demonstrate reduced cell viability and apoptosis induction after treatment with high concentration (600 μg/ml) Nickel oxide (NiO) NPs in CRC cell lines including HT-29. Several studies are indicating that nanoparticles are used for enhancement of the efficiency of 5-FU; however, to our knowledge there are no NiNPs used in combination with neither 5-FU nor the agents H2S and NO and no data is available about the synergistic effect of NiNPs and targetable mutations determines current developments toward individualized treatment. One of the new treatments for metastatic CRC (mCRC) patients is the Cetuximab which is a monoclonal antibody that acts explicitly on the epidermal growth factor receptor (EGFR). This treatment is applied to mCRC patients without a mutation in the RAS gene. The reason for this is that CRC patients with mutations in this particular gene will fail to respond to this target-direct therapy. Hence, a prescreen for the mutation before target therapy is mandatory.

In the current study, stage III and IV patients were screened for variants and polymorphisms in eNOS and CSE genes using a direct sequencing method. In this paper, the CSE gene will be reported as CTH according to the SNP database in NCBI. The eNOS gene has around 168 polymorphism. We only analyzed three polymorphisms in eNOS genes and one polymorphism in the CTH gene that has been broadly studied in the literature. The genetic features of CRC patients are summarized in Table 1. The most prominent finding in our genotypic study
is that two patients have 10 and 12 mutations in intron 4 (including single substitution, followed by duplication, large insertions as well as deletion). The current findings demonstrate the majority of heterozygous substitutions are A>G followed by CG and TG. However, this is not in line with the records found in the COSMIC database where more than 50% of the substitutions are G>A followed by G>T and T>A in the adenocarcinoma sample tissue of the colon cancer patients. Moreover, it is worth noting that our result showed the least mutations rate occurrence in 894G>T variant of eNOS and CTH gen.

To the best of our knowledge, the majority of detected mutations that occurred in selected CRC patients are not seen in the public database yet (Table 1). This might indicate that novel mutations in eNOS and CTH are validated on a specific location on a chromosome, that not previously have been described.

The findings regarding the involvement of eNOS polymorphism in cancer are controversial, likely due to considered factors such as analyzed sample size, cancer type, and the ethnic-dependent variation41. A meta-analysis study reported a significant association of eNOS intron 4, and -786T>C polymorphism in overall cancer and 894 G>T polymorphisms with the risk of breast cancer42. While another conducted meta-analysis study reported a conflicting result wherein they did not found a significant association of SNP 894 G>T with overall cancer susceptibility43. Moreover, Ulivi and his colleagues claim to have identified a specific haplotype in eNOS polymorphism (+ 894GG and VNTR4) that are significantly associated with the overall survival of mCRC patients. Therefore, the researchers consider using this identified eNOS variant to predict the efficiency of bevacizumab-based chemotherapy in mCRC patients44, and a Chinese study confirmed a significant association between the intron 4 variant and increased cancer risk in Taiwanese individuals under the age of 60 years45. One of the limitations of this study is the restricted number of analyzed samples and SNPs used in this study that limits the evaluation of the results.

Conclusions
These findings reveal that H2S could be used for enhancement of the anticancer efficiency of 5-FU in the presence of NPs in the CRC cell line, while NO could be considered as an antiapoptotic agent that enables HT 29 cells resistant to 5-FU treatment. Moreover, changing the experimental setup in future research by administering loaded NPs or venom or a combination with H2S in liposomes might deliver the agents more efficiently to the CRC cells leading to a better strategy of cancer treatment. Further investigation on the molecular level is essential to understand the mechanism by which the mutations in eNOS and CSE enzyme-producing genes perhaps could modify the role of H2S and NO in CRC patients.

Materials and methods

Cell culture. The human colorectal adenocarcinoma (HT-29 cells, IBRC C10097) were purchased from the National Cell Bank in the Iranian Biological Resource Center. These cells were grown as a monolayer in a 25 cm² culture flask with Dulbecco’s Modified Eagle Medium (DMEM high glucose, EuroClone cat: ECM0728L) containing L-glutamine. The culture media were supplemented with an antibiotic solution containing 1% (100×) Penicillin/Streptomycin (Capricorn Scientific Cat: PS-B) and 10% heat-inactivated FBS (Capricorn Scientific Cat: FBS-GI-12B) as the provision of nutrients. The cells were maintained at 37°C in a 5% CO2 humidified incubator (RS Biotech Galaxy Model R+, USA). The growth medium was changed every three days, and the viability of cells was assessed by direct observation of cells using an inverted phase-contrast microscope (Labomed, USA). The HT-29 cells were sub-cultured using 0.05% trypsin/EDTA (Capricorn Scientific cat: TRY-1B). Cell viability was assessed by staining 100 µl of cell suspension with trypan blue (0.2%), and cells were counted using a hematocytometer. All the experiments were performed using cells from passage 20 or less.

Cell morphology analysis. To find out the IC50, the cells were treated with various concentrations of Na2S, an exogenous H2S donor, ranging from (1-6 mM), SNP a NO donor, with following concentrations (3 × 10⁻³–3 × 10⁻² M) for 24hrs and 5-FU (11.25 µM) for 24, 48, 72hrs and 96hrs which expect to reach the IC50 after five days46. The morphological changes were examined using an inverted phase-contrast microscope (Labomed, USA) followed by MTT assay.

In vitro cell proliferation assay. The reduction of (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) is a method to measure and monitor cell proliferation. MTT assays were performed using the Cytoselect MTT Cell Proliferation Assay (Cell Biolabs, Inc., Cat: CBA-252, San Diego, CA, USA). After reaching 85% confluence, the HT-29 cells were trypsinized, and the cells were suspended in the growth medium, 2 × 10⁴ cells/well were seeded in a 96-well culture plate and incubated at 37°C in a humidified 5% CO2, allowed to attach for 48hrs. The cytotoxicity of the compounds was determined in a dose-dependent manner to obtain the proper concentrations of the compound for 50% inhibition of cell growth (IC50). The growth medium was then changed with the new medium and exposed with IC50 concentration of the compounds and exposed for 24hrs at the following IC50 concentrations: Na2S (5 mM), SNP (1.10⁻⁶ M), 5-FU (11.25 µM), after five days, and the combination of these compounds and each condition is tested in 6 replications. After the incubation periods, 10 µl of Cytoselect MTT cell proliferation assay reagent was added to each culture well, and the 96-well plates were incubated at 37°C for 4hrs until a purple precipitate is visible. 100 µl of a detergent solution containing dimethylsulfoxide (DMSO) was added to each well to dissolve the purple formazan product. Following 2hrs of incubation at room temperature in the dark, the absorbance was determined at a wavelength of 630 nm by an Elisa reader (BioTek Instruments, Inc., USA).

Preparation of Nickel nanoparticle suspension. Nickel nanoparticle with 40 nm in diameter size from (Sigma-Aldrich Co, St Louis, USA) was tested in this study. The method described by Abdulqader and Aziz49.
was used to prepare NiNPs with some modification. Hence, a 1 mg/ml stock solution in the growth medium was prepared, and subsequently, the suspension was vortexed and then sonicated for 30 s with an ultrasonic homogenizer (150 VT model, constructed by Biologica, Inc., Manassas, VA, USA). Next, the suspension with nickel particles was placed on ice for 5 s, and, sonicated again for 2 min, immediately before the actual incubation to avoid agglomeration. The HT-29 cells were incubated with NiNP suspension with the following concentrations (0.1–30 µg/ml) for 24 hrs, and the IC$_{50}$ of (10 µg/ml) was determined. The IC$_{50}$ of NiNP was subsequently used for treating the cells with NiNP alone or co-treatment with IC$_{50}$ concentration of the following agents, including, 5-FU, Na$_2$S, and SNP.

**Cell apoptosis assay.** The terminal deoxynucleotidyl transferase (dUTP)-nick end labelling (TUNEL) method that determines DNA-strand breaks throughout the apoptosis process was used to confirm HT-29 cells undergoing apoptosis after treatment with different compounds for different time of period. Cell Meter TUNEL (Red fluorescence) Apoptosis Assay Kit (AAT Bioquest Inc., USA, Cat: 22,844) was used according to the manufacturer’s suggestion procedure with some modifications. In short, 6 × 10$^4$ of HT-29 cells were grown for 72hrs on coverslips then treated with or without IC$_{50}$ of the following compounds; Na$_2$S (5 mM), SNP (10$^{-6}$ M), 5-FU (11.25 µM, after five days), and the combination of these compounds for 24 h, 48 h, and 72 h, 96 h, and 105 h at 37°C with 5% CO$_2$. After incubation coverslips were rinsed twice with ice-cold PBS (pH 7.4) followed by incubation with TUNEL kit reaction solution (consisting of 100× Tunelley Red 0.5 µl+ reaction buffer 50 µl) for 45 min at 37°C in a dark chamber and additional 4',6-diamidino-2-phenylindole (DAPI) stain was conducted to identify the cell nuclei. Cells with red nuclei are TUNEL-positive indicating apoptosis and apoptotic cells were visually observed using a fluorescence microscope (Euromex, Holland) equipped with sCMEX-20 Microscope Camera (Euromex, Holland). The images of total cell nuclei stained with DAPI and CRC cells stained with TUNEL fluorescent dye were captured at 100× and 1000× magnification, respectively. The quantity of TUNEL positive cells was given as a percentage of total cells counted in a minimum of six random microscopic fields.

**Collection of scorpions and their venom.** The scorpion species (*Androctonus Crassicauda* and *Hottentotta Saucaly*) were collected from different regions of northern Iraq by a professional researcher. The scorpion collection and venom isolation were carried out in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Animal Research Committee of Salahaddin University-Erbil. These arachnids were kept individually within the desirable condition and sustained with mealworms and water ad libitum. The scorpion venoms were ejected by electrical stimulation and directly used to expose the HT-29 cells with venom concentrations ranged from (0.1–1.0 mg/ml) for a period of 24hrs.

**Human CRC specimens.** CRC specimens were collected from 35 patients at different hospitals in Erbil, Iraq (PAR, CMC, Rezgary, Zheen international hospitals). This study was approved by the Human Ethics Committee of the College of Science, Salahaddin University-Erbil. The study was conducted according to the criteria set by the declaration of Helsinki, and the signed informed consent forms were obtained from the participants approving to investigate the tissue material. All CRC were histologically confirmed, and the specimens were snap-frozen in liquid nitrogen and stored at -80°C until DNA extraction.

**DNA extraction and quantification of DNA concentration.** Genomic DNA was purified from CRC tissues following the manufacturer’s protocols using the Genomic DNA Mini Kit for Tissue (Geneaid Biotech Ltd, Korea). The eluted DNA was assessed for concentration (A$_{260}$) and purity (by the measure of the A$_{260}$/A$_{280}$ ratio of 1.8). Human CRC specimens were collected from 35 patients at different hospitals in Erbil, Iraq (PAR, CMC, Rezgary, Zheen international hospitals). This study was approved by the Human Ethics Committee of the College of Science, Salahaddin University-Erbil. The study was conducted according to the criteria set by the declaration of Helsinki, and the signed informed consent forms were obtained from the participants approving to investigate the tissue material. All CRC were histologically confirmed, and the specimens were snap-frozen in liquid nitrogen and stored at -80°C until DNA extraction.

**DNA extraction and quantification of DNA concentration.** Genomic DNA was purified from CRC tissues following the manufacturer’s protocols using the Genomic DNA Mini Kit for Tissue (Geneaid Biotech Ltd, Korea). The eluted DNA was assessed for concentration (A$_{260}$) and purity (by the measure of the A$_{260}$/A$_{280}$ ratio of 1.8). Human CRC specimens were collected from 35 patients at different hospitals in Erbil, Iraq (PAR, CMC, Rezgary, Zheen international hospitals). This study was approved by the Human Ethics Committee of the College of Science, Salahaddin University-Erbil. The study was conducted according to the criteria set by the declaration of Helsinki, and the signed informed consent forms were obtained from the participants approving to investigate the tissue material. All CRC were histologically confirmed, and the specimens were snap-frozen in liquid nitrogen and stored at -80°C until DNA extraction.
of Sanger sequencing data was achieved using the Mutation Surveyor software package 5.1 (Soft Genetics), and the mutation result was compared with public databases, including gnomAD, dbSNP, ClinVar, and COSMIC.

**Statistical analysis.** The results were analyzed using GraphPad Prism 6. One-way ANOVA with Tukey's multiple comparisons test was conducted to evaluate the statistically significant differences between the anticancer activity of different agents and untreated cells. All the experiments were carried out 3 to 6 times and the data were stated as mean ± SE difference.

Received: 30 August 2020; Accepted: 18 January 2021
Published online: 28 January 2021

**References**

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. https://doi.org/10.3322/caac.21492 (2018).
2. Keum, N. & Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 16, 713–732. https://doi.org/10.1038/s41575-019-0189-8 (2019).
3. Qader, G. et al. The status of cancer publications in the Kurdistan region of Iraq. J. Cancer Policy 24, 100221. https://doi.org/10.1016/j.jcpa.2020.100221 (2020).
4. Othman, R. T. et al. Cancer incidence rates in the Kurdistan region/Iraq from 2007–2009. Asian Pac. J. Cancer Prev. APJCP 12, 1261–1264 (2011).
5. Khoshnaw, N., Mohammed, H. A. & Abdullah, D. A. Patterns of cancer in kuwait: results of eight years cancer registration in Sulaymaniyah Province-Kurdistan-Iraq. Asian Pac. J. Cancer Prev. 16, 8525–8531. https://doi.org/10.7314/apjpcp.2015.16.18.8525 (2015).
6. Kim, N. K. et al. Complete mesocolic excision and central vascular ligation for colon cancer: principle, anatomy, surgical technique, and outcomes. Surg. Oncol. 25, 252–262. https://doi.org/10.1016/j.suronc.2016.05.009 (2016).
7. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. 2020. CA Cancer J. Clin. 70, 7–30. https://doi.org/10.3322/caac.21590 (2020).
8. Vodenkova, S. et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol. Ther. 206, 107447. https://doi.org/10.1016/j.pharmacolther.2019.107447 (2020).
9. Chen, Y.-H. et al. Maintenance BEZ235 treatment prolongs the therapeutic effect of the combination of BEZ235 and radiotherapy for colorectal cancer. Cancers 11, 1204. https://doi.org/10.3390/cancers11081204 (2019).
10. Tie, J. et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5, 1710–1717. https://doi.org/10.1001/jamaoncol.2019.3616 (2019).
11. Shahjehan, F., Kamatham, S., Chandrasekharan, C. & Kasi, P. M. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. Drugs Today (Barcelona, Spain: 1998) 55, 683–693. https://doi.org/10.1358/dot.2019.55.11.3035584 (2019).
12. He, L. et al. Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. Exp. Mol. Med. 50, 101–101. https://doi.org/10.1038/s12276-018-0128-8 (2018).
13. Ghosh, A., Roy, R., Nandi, M. & Mukhopadhyay, A. Scorpion venom-toxins that aid in drug development: a review. Int. J. Pept. Res. Ther. 25, 27–37. https://doi.org/10.1007/s10991-018-9721-x (2019).
14. Xiao, H., Chen, Y. & Alnaggar, M. Silver nanoparticles induce cell death of colon cancer cells through impairing cytoskeleton and membrane nanostructure. Micron 126, 102750. https://doi.org/10.1016/j.micron.2019.102750 (2019).
15. Khan, S. et al. Preparation, characterization, and in vitro cytotoxic activity of nickel oxide nanoparticles on HT-29 and SW620 colon cancer cell lines. J. Trace Elem. Med. Biol. Organ Soc. Miner. Trace Elements (GMS) 52, 12–17. https://doi.org/10.1016/j.jtemb.2018.11.003 (2019).
16. Kolluru, G. K., Shen, X., Yuan, S. & Kevil, C. G. Gasotransmitter heterocellular signaling. Antioxid. Redox Signal. 26, 936–960. https://doi.org/10.1089/ars.2016.6909 (2017).
17. Pietrangeli, P. et al. Lathyrus sativus diamine oxidase counteracts histamine-induced cell proliferation, migration and proangiogenic mediators release in human colon adenocarcinoma cell line Caco-2. Phytother. Res. PTR 33, 1878–1887. https://doi.org/10.1002/tr.6378 (2019).
18. Li, K. et al. Microcystins-LR induced apoptosis via S-nitrosylation of GAPDH in colorectal cancer cells. Ecotoxicol. Environ. Saf. 190, 110996. https://doi.org/10.1016/j.ecosaf.2019.110996 (2020).
19. Ehrenfeld, P., Cordova, E., Duran, W. N. & Sanchez, F. A. S-nitrosylation and its role in breast cancer angiogenesis and metastasis. Nitric Oxide Biol. Chem. 87, 52–59. https://doi.org/10.1016/j.niox.2019.03.002 (2019).
20. Szabo, C. Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat. Rev. Drug Discov. 15, 185–203. https://doi.org/10.1038/nrd515 (2016).
21. Cao, X. et al. A review of hydrogen sulfide synthesis, metabolism, and measurement: is modulation of hydrogen sulfide a novel therapeutic for cancer?. Antioxid. Redox Signal. 31, 1–38. https://doi.org/10.1089/ars.2017.7058 (2019).
22. Ishizuuka, Y. et al. Expression profiles of NOS isoforms in dental pulp and odontoblasts in nNOS knockout mice. Bull. Tokyo Dent. College 60, 261–266. https://doi.org/10.2099/tdpc.2020.0003 (2019).
23. Xu, W., Liu, L. Z., Loizidou, M., Ahmed, M. & Charles, I. G. The role of nitric oxide in cancer. Cell Res. 12, 311–320. https://doi.org/10.1038/s7290133 (2002).
24. Olah, G. et al. Role of endogenous and exogenous nitric oxide, carbon monoxide and hydrogen sulfide in HCT116 colon cancer cell proliferation. Biochem. Pharmacol. 149, 186–204. https://doi.org/10.1016/j.bcp.2017.10.011 (2018).
25. Chung, P. et al. Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism. Nitric Oxide Biol. Chem. 8, 119–126. https://doi.org/10.1016/s1089-8603(02)01477-7 (2003).
26. Al-Asmari, A. K., Ullah, Z., Al Balowi, A. & Islam, M. In vitro determination of the efficacy of scorpion venoms as anti-cancer agents against colorectal cancer cells: a nano-liposomal delivery approach. Int. J. Nanomed. 12, 539–574. https://doi.org/10.2147/IJN.S123514 (2017).
27. Al-Asmari, A. K., Riyasdeen, A., Abbasmanthiri, R., Arshaduddin, M. & Al-Harthi, F. A. Scorpion (Androctonus bicolor) venom exhibits cytotoxicity and induces cell cycle arrest and apoptosis in breast and colorectal cancer cell lines. Indian J. Pharmacol. 48, 537–543. https://doi.org/10.4103/0253-7613.190742 (2016).
28. Zargaran, J. et al. Scorpio (Androctonus crassicauda) venom limits growth of transformed cells (SH-SYSY and MCF-7) by cytotoxicity and cell cycle arrest. Exp. Mol. Pathol. 91, 447–454. https://doi.org/10.1016/j.xepm.2011.04.008 (2011).
29. Mikaelian, A. G. et al. Pleiotropic anticancer properties of scorpion venom peptides: rhapalurus princeps venom as an anticancer agent. Drug Des. Devel. Ther. 14, 881–893. https://doi.org/10.2147/DDDT.S231008 (2020).
30. Attoub, S., Arafat, K., Khalaf, T., Sulaiman, S. & Iratni, R. Frondoside a enhances the anti-cancer effects of oxaliplatin and 5-fluorouracil on colon cancer cells. *Nanomedicine* **2018**. https://doi.org/10.1038/s41598-021-82244-x

31. Kukcinaviciute, E. *The dichotomous role of H2S in cancer cell biology? Deja vu all over again.* Biochem. Pharmacol. **149**, 205–223. https://doi.org/10.1016/j.bcp.2018.01.042 (2018).

32. Szabo, C. *et al.* Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. *Proc Natl Acad Sci USA* **110**, 12474–12479. https://doi.org/10.1073/pnas.1306241110 (2013).

33. Miyamoto, R. *et al.* Polysulfides (H(2)S(n)) produced from the interaction of hydrogen sulfide (H(2)S) and nitric oxide (NO) activate TRPA1 channels. *Sci. Rep.* **7**, 45995. https://doi.org/10.1038/srep45995 (2017).

34. Soyemi, S., Chattopadhyay, M. & Kashfi, K. NOSH-aspirin alone or in combination with 5-fluorouracil induces tumor regression in a xenograft model of estrogen receptor positive breast cancer. *Can. Res.* **74**, 2513–2513. https://doi.org/10.1158/1538-7445.AM2014-2513 (2014).

35. Yue, T. *et al.* Amino-oxyacetic acid (AOAA) sensitizes colon cancer cells to oxaliplatin via exaggerating apoptosis induced by ROS. *J. Cancer* **11**, 1828–1838. https://doi.org/10.7150/jca.35375 (2020).

36. Reddy, E. *et al.* Tumor growth inhibition of A549 cells using Aminooxyacetic acid (AOAA) sensitizes colon cancer cells to oxaliplatin via exaggerating apoptosis induced by ROS. *Oxidative Med. and Cellular Longevity* **2018**, 1–7. https://doi.org/10.1155/2018/3507524 (2018).

37. Chang, C. *et al.* Cancer cells are protected against the cytotoxic effect of oxaliplatin by NOSH-aspirin. *Sci. Rep.* **7**, 15782. https://doi.org/10.1038/s41598-017-17101-w (2017).

38. Perez-Herrero, E. & Fernandez-Medarde, A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. *Eur. J. Pharm Biopharm.* **93**, 9–29. https://doi.org/10.1016/j.ejpb.2015.03.018 (2015).

39. Abdulqadir, S. Z. & Aziz, F. M. Internalization and effects on cellular ultrastructure of nickel nanoparticles in rat kidneys. *Int. J. Nanomed.* **14**, 3995–4005. https://doi.org/10.2147/ijn.s200999 (2019).

40. Bohanes, P., Labonte, M. J., Winder, T. & Lenz, H. J. Predictive molecular classifiers in colorectal cancer. *Semin. Oncol.* **38**, 576–587. https://doi.org/10.1053/j.seminoncol.2011.05.012 (2011).

41. Nan, J., Liu, Y., Xu, C. & Ge, D. Effects of eNOS gene polymorphisms on individual susceptibility to cancer: a meta-analysis. *Nitr. Oxide Biol. Chem.* **84**, 1–6. https://doi.org/10.1080/10775144.2018.1383606 (2019).

42. Gao, X., Wang, J., Wang, W., Wang, M. & Zhang, J. eNOS genetic polymorphisms and cancer risk: a meta-analysis and a case-control study of breast cancer. *Medicine (Baltimore)* **94**, e972. https://doi.org/10.1097/MD.0000000000000975 (2015).

43. Haque, S. *et al.* G894T and 4a/b polymorphisms of NOS3 gene are not associated with cancer risk: a meta-analysis. *Asian Pac. J. Cancer Prev.* **16**, 2929–2937. https://doi.org/10.7314/apjcp.2015.16.7.2929 (2015).

44. Ulivi, P. *et al.* eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. *J. Transl. Med.* **13**, 258. https://doi.org/10.1186/s12967-015-0619-5 (2015).

45. Yeh, C. C., Santella, R. M., Hsieh, L. L., Sung, F. C. & Tang, R. An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. *J. Cancer Prev.* **19**, 1828–1838. https://doi.org/10.7150/jca.35375 (2020).

46. Tawfik, E., Ahamed, M., Almalik, A., Alfageeh, M. & Alishamsan, A. Prolonged exposure of colon cancer cells to 5-fluorouracil nanoparticles improves its anticancer activity. *Saudi Pharm. J.* **25**, 206–213. https://doi.org/10.1016/j.sjps.2016.05.010 (2017).

Acknowledgements
We thank Prof Falah Aziz and Dr Shang Z. Abdulqader for their generous donation of NiNPs and TUNEL assay kit and Dr Fenek Sherzad and Mr Ayoub for collecting the scorpions and helping with extracting its venom. We also want to thank the Research Centre, Salahaddin University-Erbil for providing cell culture equipment and instruments. Finally, a sincere thank goes to Soma Housein from Cardiff University for her diligent proofreading of this article.

Author contributions
Z.H. performed experiments and co-wrote the paper, T.S.K. designed the experiments and A.S. wrote the experiments, analyzed data and co-wrote the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to A.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021